Metabolic Syndrome. Other disorders of lipoprotein metabolism
Conditions
Interventions
Intervention 1: Intervention group:Q10,100 mg soft gel capsule twice a day for 3 month. Intervention 2: Placebo group: placebo tablets containing 100 mg of soy oil twice a day for 3 months.
Treatment - Drugs
Intervention group:Q10,100 mg soft gel capsule twice a day for 3 month
Placebo group: placebo tablets containing 100 mg of soy oil twice a day for 3 months
Sponsors
Yazd University Of Medical Sciences
Eligibility
Sex/Gender
All
Age
35 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. Having the metabolic syndrome according to the NCEP ATP III definition: According to the NCEP ATP III definition of having at least 3 of the following conditions: a)Abdominal obesity (waist circumference =102 cm in men and= 88 cm in women) b) High blood pressure (systolic blood pressure=130 mm Hg and / or diastolic blood pressure=85 mm Hg) c)Low HDL-C (< 40 mg/ dl in men and < 50 mg/ dl in women) d)TG =150 mg/ dl e)FBS =100 mg/ dl 2.Being the age limit from 35 to 55 years 3.Patients with hypertension treated with anti-hypertensive drugs in the past 3 months have not changed and changes in drug therapy not occure during the study period. 4.Patients with diabetes who their treatment in the past 6 weeks has not changed (Changes in drug therapy not occur during the study period ) 5. Consent to participate in the study. Exclusion criteria: 1.Statin use in the last month 2.History of cardiovascular disease in the past three months 3.Having an active infection 4.Risk of renal failure 5.Liver disease (viral hepatitis, treatments for liver disease) 6.Alcohol Consumption 7.Pregnancy or taking contraceptive drugs 8.History of hospitalization in the past 2 months 9.consumption of Nutritional supplements such as vitamins, trace elements, antioxidants
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting Plasma Glucose. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzymatic methods.;HDL Cholesterol. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: colorimetry.;Blood pressure. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: sphygmomanometer.;Waist circumference. Timepoint: at the begining of the study and3 month after intervention. Method of measurement: tape.;TG. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzymatic methods.;Malondialdehyde. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: thiobarbituric acid method.;Hs-CRP. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: ELISA.;Homocysteine. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: colorimetry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Total cholesterol. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: colorimetry.;Anthropometric indicators: weight, height, body mass index, waist circumference, hip circumference and waist to hip ratio. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Standard procedures using scale, tape and equations.;LDL cholesterol. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: colorimetry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Gholamreza Usefzadeh
Kerman Physiology Research Center
Outcome results
None listed